STOCK TITAN

HeartBeam, Inc. - $BEAT STOCK NEWS

Welcome to our dedicated page for HeartBeam news (Ticker: $BEAT), a resource for investors and traders seeking the latest updates and insights on HeartBeam stock.

HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.

HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.

Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.

One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.

HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.

Latest News: Source: HeartBeam, Inc.

  • ------
  • ------
  • ------
Rhea-AI Summary

HeartBeam (NASDAQ: BEAT) announced new study data showing that its AI algorithm combined with vectorcardiography (VCG) outperformed expert cardiologists in detecting atrial flutter, a common arrhythmia. The study, presented at the Heart Rhythm Society annual meeting, involved 173 VCGs, single-lead ECGs, and 12-lead ECGs. Key findings revealed a 40% improvement in detection sensitivity compared to single-lead ECGs reviewed by cardiologists and a 6% improvement over 12-lead ECGs. HeartBeam's core technology captures heart signals in three projections, aiming for a more personalized cardiac care approach. Their AIMIGo™ device, for patient use, is under FDA review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
none
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has won the 'Best New ECG Technology Solution' award in the 8th annual MedTech Breakthrough Awards for their HeartBeam AIMIGo™ device. The AIMIGo™ device is a credit card-sized tool that allows for remote evaluation of cardiac symptoms, capturing heart signals in three projections and synthesizing them into a 12-lead ECG. The device is currently under FDA review and aims to provide a personalized approach to cardiac care outside of medical facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) reported positive results for its AIMIGo™ 3D VECG system, showcasing progress in clinical and regulatory milestones. The company anticipates FDA clearance by Q2 2024 for the AIMIGo system and plans for a launch by 2024 end. The VALID-ECG pivotal study for the 12-Lead Synthesis Software submission is underway, aiming to demonstrate similarity with a standard 12-lead ECG. HeartBeam AI showed improved performance in detecting arrhythmias, supported by new patents and positive data presented at EHRA conference. Cash and cash equivalents stood at approximately $12.6 million as of March 31, 2024, enabling future clinical and regulatory milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on May 9, 2024, to discuss its first-quarter results, regulatory updates, ongoing initiatives, and 2024 milestones. CEO Branislav Vajdic, President Robert Eno, and Consulting CFO Richard Brounstein will lead the call. Investors can access the webcast or call in using the provided details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
conferences earnings
-
Rhea-AI Summary
HeartBeam, Inc. (BEAT) presents groundbreaking data at EHRA conference showcasing the efficacy of HeartBeam AI in detecting atrial flutter. The study reveals a 28% improvement over single-lead ECGs, aligning with 12-lead ECG performance standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) reports financial and operational results for Q4 and full year 2023, highlighting progress in clinical and regulatory milestones for the AIMIGo™ 3D VECG system. The company anticipates FDA clearance for the AIMIGo system by Q2 2024 and aims to launch AIMIGo by the end of 2024. Recent patents on core VECG technology and AI program developments enhance the company's intellectual property and diagnostic capabilities. Financially, R&D and G&A expenses increased, resulting in a net loss for Q4 and full year 2023. Cash and cash equivalents stood at $16.2 million as of December 31, 2023, supporting upcoming milestones and extending cash runway into early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) has enrolled the first patients in the VALID-ECG pivotal study to evaluate the performance of their 12-lead ECG synthesis software for arrhythmia detection. The study aims to compare the synthesized ECG with a standard hospital-based ECG using quantitative and qualitative methodologies. AIMIGo, the technology behind the study, utilizes 3D VECG technology to capture signals in three projections and synthesize a 12-lead ECG. The study marks a significant advancement in cardiac monitoring technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) secures two new patents for its core vectorelectrocardiography (VECG) technology, bringing the total to 14 US and 4 international patents. The innovative VECG technology collects 3D heart signals and converts them into a 12-lead ECG, enabling monitoring outside medical facilities with portable devices. CEO Branislav Vajdic emphasizes the strategic importance of protecting their product pipeline for revolutionizing cardiac care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.54%
Tags
none
-
Rhea-AI Summary
HeartBeam, Inc. (BEAT) will host a conference call on March 20, 2024, to discuss its Q4 and full-year 2023 results, along with regulatory updates and 2024 milestones. CEO Branislav Vajdic, President Robert Eno, and other key executives will lead the call. Investors can access the call and presentation via webcast or phone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences earnings
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) appoints Mohammad Shokoohi-Yekta to lead program and industry pioneer Lance Myers as advisor. The company aims to transform cardiac care through personalized insights using AI and VECG technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
AI

FAQ

What does HeartBeam, Inc. do?

HeartBeam, Inc. develops high-resolution ambulatory ECG solutions for detecting and monitoring cardiac disease outside traditional healthcare settings.

What is unique about HeartBeam's technology?

HeartBeam's technology includes a credit card-sized ECG device and a cloud-based diagnostic system that performs as well as top cardiologists in diagnosing heart attacks.

How does HeartBeam's iCardiologist application work?

The iCardiologist application uses AI and machine learning to continuously improve its diagnostic accuracy and predictive capabilities, assisting cardiologists in patient analysis.

What is VECG technology?

VECG stands for Vector Electrocardiography, a proprietary and patented platform developed by HeartBeam to provide higher-resolution ECG solutions.

Has HeartBeam's technology been validated?

Yes, studies by Harvard Medical School faculty have shown that HeartBeam's performance is equal to or better than world-class cardiologists in diagnosing heart attacks.

Is HeartBeam seeking FDA clearance?

Yes, HeartBeam is currently seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

What are the benefits of HeartBeam's ECG solutions?

HeartBeam's solutions offer accessible, high-resolution cardiac monitoring useful outside of traditional healthcare settings, providing early detection and monitoring of cardiac conditions.

Can HeartBeam's technology locate a heart attack?

Yes, the technology can help cardiologists locate a heart attack on a 3D model of the heart using personalized diagnostic thresholds and novel ECG markers.

How is HeartBeam improving cardiac care?

HeartBeam is improving cardiac care by developing practical, high-resolution ECG solutions that provide critical diagnostic tools accessible outside traditional healthcare environments.

Where can I find the latest news on HeartBeam, Inc.?

The latest news and updates on HeartBeam, Inc. can be found on StockTitan and other financial news platforms.

HeartBeam, Inc.

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

60.56M
19.29M
28.17%
8.8%
0.61%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SANTA CLARA